CLINICAL TRIALS PROFILE FOR MESNEX

All Clinical Trials for MESNEX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002804 ↗	Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Children With Advanced Soft Tissue Sarcoma	Completed	National Cancer Institute (NCI)	Phase 2	1996-09-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, surgery, and radiation therapy in treating children who have advanced soft tissue sarcoma.
NCT00002804 ↗	Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Children With Advanced Soft Tissue Sarcoma	Completed	Children's Oncology Group	Phase 2	1996-09-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, surgery, and radiation therapy in treating children who have advanced soft tissue sarcoma.
NCT00002816 ↗	Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia	Completed	National Cancer Institute (NCI)	Phase 3	1996-12-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy in treating children who have relapsed acute lymphoblastic leukemia.
NCT00002816 ↗	Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia	Completed	Children's Oncology Group	Phase 3	1996-12-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy in treating children who have relapsed acute lymphoblastic leukemia.
NCT00002829 ↗	Bone Marrow Transplantation in Treating Patients With Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	1994-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells, and may be an effective treatment for lymphoma. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating patients with recurrent or residual low-grade lymphoma.
NCT00002829 ↗	Bone Marrow Transplantation in Treating Patients With Lymphoma	Completed	M.D. Anderson Cancer Center	Phase 2	1994-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells, and may be an effective treatment for lymphoma. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating patients with recurrent or residual low-grade lymphoma.
NCT00002875 ↗	Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma	Completed	National Cancer Institute (NCI)	Phase 3	1996-12-01	RATIONALE: Radiation therapy uses high energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective when combined with radiation therapy for treating medulloblastoma. PURPOSE: Randomized phase III trial to compare two combination chemotherapy treatments plus radiation therapy in treating children with newly diagnosed medulloblastoma.

Clinical Trial Conditions for MESNEX

Condition Name

Condition Name for MESNEX
Intervention	Trials
Leukemia	14
Lymphoma	12
Sarcoma	7
Acute Lymphoblastic Leukemia	7

Condition MeSH

Condition MeSH for MESNEX
Intervention	Trials
Leukemia	29
Precursor Cell Lymphoblastic Leukemia-Lymphoma	26
Leukemia, Lymphoid	24
Lymphoma	16

Clinical Trial Locations for MESNEX

Trials by Country

Trials by Country for MESNEX
Location	Trials
United States	447
Canada	48
Australia	15
Poland	6
Puerto Rico	6

Trials by US State

Trials by US State for MESNEX
Location	Trials
Texas	46
Illinois	20
Tennessee	20
New York	16
Ohio	14

Clinical Trial Progress for MESNEX

Clinical Trial Phase

Clinical Trial Phase for MESNEX
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	7
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for MESNEX
Clinical Trial Phase	Trials
Completed	33
Terminated	22
Recruiting	22

Clinical Trial Sponsors for MESNEX

Sponsor Name

Sponsor Name for MESNEX
Sponsor	Trials
M.D. Anderson Cancer Center	30
National Cancer Institute (NCI)	23
Children's Oncology Group	10

Sponsor Type

Sponsor Type for MESNEX
Sponsor	Trials
Other	108
NIH	25
Industry	22

Last updated: April 23, 2026

Mesnex (mesna) Clinical Trials Update, Market Analysis, and Projection

Mesnex is a brand of mesna (sodium 2-mercaptoethanesulfonate), an agent used to reduce the risk of urothelial toxicity (hemorrhagic cystitis) from ifosfamide and cyclophosphamide chemotherapy exposure. In the U.S., Mesnex is marketed by Baxter. The clinical and market landscape for mesna is shaped by: (1) long-established guideline use with chemotherapy regimens, (2) widespread availability of generic mesna, and (3) low innovation cadence because the active ingredient has long tenure and limited patent-driven differentiation.

---

What is Mesnex used for clinically?

Mesna is administered alongside urotoxic chemotherapy to prevent or mitigate:

• Hemorrhagic cystitis and urinary tract bleeding
• Urothelial injury linked to chemotherapy metabolites

Clinical positioning is tied to chemotherapy protocols rather than standalone indication expansion. In practice, mesna use scales with volumes of regimens that include ifosfamide/cyclophosphamide and with institutional adherence to supportive-care protocols.

---

What is the clinical trials update for Mesnex?

A current “trial update” depends on whether one tracks: 1) trials of mesna as the active ingredient, 2) trials of combination regimens in which mesna is used as supportive care, and 3) formulation or device studies.

No actionable, newly progressing late-stage mesna-only efficacy/safety programs were identifiable for Mesnex specifically through standard public trial registries under the drug’s brand name, and mesna’s clinical role typically appears in supportive arms of oncology studies rather than as a primary endpoint driver. The practical consequence for R&D and investing: the upside from “clinical development” is limited to protocol-driven inclusion, not new registration pathways for mesna itself.

Where updates typically show up:

• Oncology trials that include ifosfamide/cyclophosphamide supportive regimens continue to report safety outcomes that incorporate mesna use.
• Comparative supportive-care protocols may affect mesna dosing schedules and administration routes, but those changes usually do not create new regulatory value for an already mature active ingredient.

---

How does mesna’s evidence base affect registration risk?

Mesna’s regulatory footprint is mature; it is widely accepted supportive care. That maturity changes the risk profile:

• Lower probability of “new evidence” generating major label expansion
• Higher probability that new studies refine dosing schedules and supportive-care workflow rather than create new endpoints

This dynamic limits the market impact of “clinical trial updates” unless new dosing/formulation creates measurable adoption changes (e.g., reduced administration burden for inpatient/outpatient workflows), or unless new chemotherapy regimens expand the eligible population.

---

Who buys Mesnex and where does demand originate?

Demand is driven by oncology care settings where urotoxic chemotherapy is delivered:

• Hospital inpatient oncology
• Outpatient chemotherapy infusion centers
• Academic cancer centers with standardized supportive-care order sets

Procurement is typically through:

• Contract pharmacy purchasing
• GPO-negotiated tenders
• Pharmacy and therapeutics committee formularies that require supportive-care alignment with regimen protocols

Because mesna is supportive rather than disease-modifying, formulary decisions often focus on:

• Price and supply stability
• Administration practicality
• Institutional protocol compliance

---

What is the competitive landscape?

Mesna is largely exposed to generic competition. Brand-level economics for Mesnex depend on:

• Remaining brand-share where contracts and switching costs delay full generic adoption
• Institutional adoption of a preferred product format and dosing schedule
• Supply chain stability and rebate dynamics under contracted pricing

Implication for market projection: even with stable underlying chemotherapy volumes, Mesnex’s share and revenue growth depend more on pricing and distribution than on incremental uptake from new trials.

---

What drives market size for Mesnex?

The addressable market is anchored to chemotherapy usage patterns:

• Utilization intensity of ifosfamide and cyclophosphamide
• Treatment line mix across solid tumors and hematologic malignancies
• Shifts in supportive-care protocols
• Geographic prescribing variation and adoption of standardized supportive-care pathways

Supportive care adoption tends to track chemotherapy exposure and safety monitoring intensity, not novel oncology adoption alone.

---

Market analysis: where Mesnex sits in oncology supportive care

Mesna is best modeled as a volume-linked supportive-care product:

• Revenue scales with chemotherapy regimen frequency
• Unit economics depend on whether the institution uses branded or generic mesna
• Uptake changes are often indirect, driven by oncology regimen choice and dosing practice

A credible projection framework therefore relies on:

• Chemotherapy regimen volume trends (ifosfamide/cyclophosphamide)
• Expected generic penetration at the point of use
• Price trend assumptions under competitive procurement

---

What market projection is feasible without new clinical breakthroughs?

Given mesna’s mature status and generic availability, baseline projection should be treated as low-growth to flat for brand-level revenue, with potential decline from price compression and share drift.

A business-plausible direction (not a forecast figure without registry-level and payer-level pricing inputs) is:

• Underlying supportive-care usage stays stable if chemotherapy usage stays stable
• Net brand revenue may decline as generic share increases and procurement pushes toward lower-priced equivalents
• Any growth case requires either:
  • regimen utilization expansion, or
  • a product differentiation that reduces administration friction enough to influence contract outcomes

---

What would change the trajectory for Mesnex?

Mesna’s commercial slope changes if there is:

• A meaningful shift toward higher ifosfamide/cyclophosphamide exposure regimens
• A broad guideline update tightening supportive-care requirements in new patient subsets
• A formulation or administration change that improves workflow (fewer doses, easier outpatient administration, lower labor cost)
• Supply disruptions that temporarily tilt purchasing back toward available brands

In the absence of those catalysts, mesna’s profile remains closer to a “supportive care utility” product than a growth franchise.

---

Key regulatory and label status (implications for R&D)

Mature label status reduces the value of incremental trials focused on clinical endpoints. New development efforts typically target:

• Dosing convenience
• Safety workflow optimization
• Simplified administration protocols
• Potentially new supportive indications within defined chemo contexts, if regulators accept expanded use through supportive evidence

This is why the “trial update” for mesna rarely maps to a traditional late-stage pipeline valuation.

---

Key Takeaways

• Mesnex (mesna) is established supportive care that reduces urothelial toxicity from ifosfamide/cyclophosphamide; demand is linked to chemotherapy utilization and protocol adherence.
• Clinical “trial updates” for mesna are generally incremental and appear more as supportive protocol usage in oncology studies than as standalone late-stage development aimed at label expansion.
• Competitive pressure from generic mesna dominates; brand revenue outlook is primarily a function of pricing, procurement contracting, and supply continuity rather than new efficacy differentiation.
• Market projection expectation is stable-to-declining brand economics unless chemotherapy exposure patterns expand or a product-form factor change shifts purchasing behavior.

---

FAQs

1) Is Mesnex used to treat cancer directly?
No. Mesnex (mesna) is used to prevent or reduce chemotherapy-associated urothelial toxicity, especially hemorrhagic cystitis.

2) Why don’t mesna clinical trials drive brand growth like novel oncology drugs?
Because mesna is supportive care with mature regulatory status and broad generic availability; most studies do not create differentiated endpoints that enable new registration-driven adoption.

3) What most affects Mesnex demand?
The frequency of ifosfamide and cyclophosphamide use and how reliably institutions follow protocol-based mesna supportive care.

4) How does generic competition impact Mesnex revenue?
It compresses price and pushes purchasing toward the lowest contracted option, limiting branded revenue growth even when total supportive care volume remains steady.

5) What kinds of developments would most improve Mesnex market outlook?
Product or workflow improvements that reduce administration burden and drive contract selection, or chemotherapy regimen shifts that increase eligible exposure.

---

References (APA)

[1] FDA. (n.d.). Mesnex (mesna) prescribing information. U.S. Food and Drug Administration.
[2] Drugs@FDA. (n.d.). Mesnex (mesna) drug details and labeling. U.S. Food and Drug Administration.
[3] ClinicalTrials.gov. (n.d.). Search results for mesna. National Library of Medicine.
[4] Baxter. (n.d.). Mesnex product information. Baxter.